阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

未开盘 03-25 16:00:00 EDT

187.14

+1.36

+0.73%

盘后187.14

+0.000.00%

19:32 EDT

最高188.72	最低186.44	成交量148.40万
今开187.67	昨收185.78	日振幅1.23%
总市值2,903亿	流通市值2,889亿	总股本15.51亿
成交额2.78亿	换手率0.10%	流通股本15.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":187.14,"timestamp":1774468800000,"preClose":185.78,"halted":0,"volume":1483981,"hourTrading":{"tag":"盘后","latestPrice":187.14,"preClose":187.14,"latestTime":"19:32 EDT","volume":5403,"amount":1011205.48,"timestamp":1774481522159,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.007320486597050195,"floatShares":1544000000,"shares":1551000000,"eps":6.54,"marketStatus":"未开盘","change":1.36,"latestTime":"03-25 16:00:00 EDT","open":187.67,"high":188.72,"low":186.435,"amount":278284130.6174,"amplitude":0.012299,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.54,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774512000000},"marketStatusCode":0,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":185.78,"dividendRate":0.016777,"preHourTrading":{"tag":"盘前","latestPrice":187.4,"preClose":185.78,"latestTime":"09:29 EDT","volume":7494,"amount":1402601.7702,"timestamp":1774445399084,"change":1.62,"changeRate":0.00872,"amplitude":0.011304},"postHourTrading":{"tag":"盘后","latestPrice":187.14,"preClose":187.14,"latestTime":"19:32 EDT","volume":5403,"amount":1011205.48,"timestamp":1774481522159,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.892024,"impliedVol":0.2976,"impliedVolPercentile":0.6614},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2620639226","title":"外资再加码！医药巨头阿斯利康核药生产供应基地落子黄埔","url":"https://stock-news.laohu8.com/highlight/detail?id=2620639226","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620639226?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:36","pubTimestamp":1773927412,"startTime":"0","endTime":"0","summary":"3月19日，阿斯利康与广州经济技术开发区管理委员会正式签署战略合作框架协议，宣布将在广州开发区、黄埔区建设放射性偶联药物（RDC）生产供应基地。这是阿斯利康今年1月宣布系列投资中的重要一环，标志着这家全球生物医药巨头在核药这一前沿赛道完成战略布局的关键落子。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603193677730187.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677730187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765992.SGD","09939","AZN","LU0289739699.SGD","LU0058720904.USD","LU0109394709.USD","LU2417539215.USD","LU1829250122.USD","BK4588","IE00B3T34201.USD","LU2456880835.USD","LU2236285917.USD","BK4007","LU0889565916.HKD","BK4585","BK4568","BK1161","BK1515","159938","LU2462157665.USD","BK1574"],"gpt_icon":0},{"id":"2620003241","title":"阿斯利康将于广州建设放射性偶联药物生产供应基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2620003241","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620003241?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:01","pubTimestamp":1773918091,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4568","BK4588","LU0058720904.USD","LU0289739699.SGD","AZN","LU1829250122.USD","BK4585","LU0320765992.SGD","LU2456880835.USD","LU2417539215.USD","LU0889565916.HKD","LU2236285917.USD","IE00B3T34201.USD","LU2462157665.USD","LU0109394709.USD","BK4007"],"gpt_icon":0},{"id":"1111610205","title":"Talzenna联合Xtandi显著改善转移性前列腺癌患者的影像学无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1111610205","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111610205?lang=zh_cn&edition=full","pubTime":"2026-03-19 18:46","pubTimestamp":1773917215,"startTime":"0","endTime":"0","summary":"一项最新研究显示，将Talzenna与Xtandi联合使用，可显著提升转移性前列腺癌患者的影像学无进展生存期。这一积极结果有望为晚期前列腺癌的治疗提供新的有效方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","LU0306807586.USD","BK4599","BK4592","LU0058720904.USD","SG9999002232.USD","SGXZ57979304.SGD","BK4568","BK4007","LU0170899867.USD","IE00BLSP4452.SGD","BK4585","BK4533","IE0002270589.USD","LU0985481810.HKD","IE000M9KFDE8.USD","LU0122379950.USD","BK4581","AZN","LU1023059063.AUD","LU0225771236.USD","LU1883839398.USD","PFE","LU0225284248.USD","SG9999011175.SGD","IE00BBT3K403.USD","LU1057294990.SGD","LU0234572021.USD","SG9999003800.SGD","SG9999001176.SGD","SG9999002224.SGD","LU0456855351.SGD","LU0868494617.USD","LU1894683348.USD","SG9999013999.USD","LU1066053197.SGD","LU0289739699.SGD","SG9999001176.USD","BK4588","LU0321505439.SGD","LU1894683264.USD","IE00B19Z3B42.SGD","BK4550","LU1066051498.USD","BK4534","LU0321505868.SGD"],"gpt_icon":0},{"id":"2620021540","title":"落子上海细胞治疗全链条，阿斯利康“深耕中国”迈入新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2620021540","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620021540?lang=zh_cn&edition=full","pubTime":"2026-03-19 12:52","pubTimestamp":1773895925,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛上海报道在英国首相斯塔默访华带来中英经贸暖风的两个月后，英国制药巨头阿斯利康用实际行动为这一轮双边合作添上了浓墨重彩的一笔。3月19日，阿斯利康正式宣布了一项具有里程碑意义的布局：计划在上海建立细胞疗法商业化生产供应基地与创新中心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603193677171431.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677171431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","IE00B3T34201.USD","LU0889565916.HKD","LU1829250122.USD","LU2236285917.USD","BK4588","LU0289739699.SGD","LU0320765992.SGD","BK4007","LU2417539215.USD","LU2456880835.USD","BK4568","LU2462157665.USD","LU0109394709.USD","AZN","LU0058720904.USD"],"gpt_icon":0},{"id":"2620290003","title":"阿斯利康宣布在上海建立细胞疗法商业化生产供应基地与创新中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2620290003","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620290003?lang=zh_cn&edition=full","pubTime":"2026-03-19 10:54","pubTimestamp":1773888854,"startTime":"0","endTime":"0","summary":"南方财经3月19日电，阿斯利康今日宣布，计划在上海建立细胞疗法商业化生产供应基地与创新中心，将成为首家在中国拥有端到端细胞治疗能力的全球领先生物制药企业。同日，公司与上海市科学技术委员会及英国领先科研与金融机构签署多方合作谅解备忘录。据悉，阿斯利康将在上海自贸区临港新片区建设专门的细胞疗法商业化生产供应基地，用于在中国及其他亚洲市场商业化生产及供应自体CAR-T细胞疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677128937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AZN","LU0058720904.USD","LU1829250122.USD","LU2462157665.USD","LU0289739699.SGD","LU2236285917.USD","IE00B3T34201.USD","LU2417539215.USD","LU0889565916.HKD","BK4568","LU0320765992.SGD","BK4007","LU2456880835.USD","BK4585","LU0109394709.USD","BK4588"],"gpt_icon":0},{"id":"2620297573","title":"阿斯利康中国区副总裁黄彬突然离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2620297573","media":"消费日报财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620297573?lang=zh_cn&edition=full","pubTime":"2026-03-19 09:59","pubTimestamp":1773885577,"startTime":"0","endTime":"0","summary":"3月18日，阿斯利康中国方面向记者确认，公司资深高管、阿斯利康中国副总裁、市场准入部门负责人黄彬正式离任。该人士为阿斯利康任职超20年的元老级高管，主导中国市场准入核心业务。截至记者发稿，黄彬本人暂未对外披露后续职业安排。公开资料显示，黄彬，1967年生，中国国籍，无境外永久居留权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677031788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0058720904.USD","AZN","BK4588","LU0289739699.SGD","LU2236285917.USD","LU2462157665.USD","BK4568","LU0320765992.SGD","LU1829250122.USD","IE00B3T34201.USD","LU2456880835.USD","LU0889565916.HKD","BK4585","BK4007","LU0109394709.USD","LU2417539215.USD"],"gpt_icon":0},{"id":"2619049151","title":"阿斯利康(AZN.US)两款肿瘤药将接受FDA专家小组审判","url":"https://stock-news.laohu8.com/highlight/detail?id=2619049151","media":"智通财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619049151?lang=zh_cn&edition=full","pubTime":"2026-03-13 07:00","pubTimestamp":1773356416,"startTime":"0","endTime":"0","summary":"近日，FDA官网宣布将在2026年4月30日召开肿瘤药物咨询委员会(ODAC)会议。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313070054_25816.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313070054_25816.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4568","BK4588","BK4007","LU0058720904.USD","LU2236285917.USD","LU0289739699.SGD","LU2456880835.USD","AZN","LU1829250122.USD","BK4585","LU2462157665.USD","LU0320765992.SGD","LU0889565916.HKD","IE00B3T34201.USD","LU2417539215.USD","LU0109394709.USD","LABU"],"gpt_icon":0},{"id":"2618130770","title":"Abivax否认法国媒体报道的阿斯利康收购传闻","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130770","media":"环球市场播报","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618130770?lang=zh_cn&edition=full","pubTime":"2026-03-12 23:07","pubTimestamp":1773328020,"startTime":"0","endTime":"0","summary":"法国生物技术公司Abivax周四否认法国媒体关于阿斯利康正在谈判收购该公司的报道。\n　　此前La Lettre的报道称，阿斯利康自2月初以来一直拥有接触Abivax数据的独家权限，并有直到3月23日的时间来正式提出收购要约。\n　　Abivax发言人表示，他们完全否认这一报道，但没有进一步评论文章中的具体内容。阿斯利康早些时候拒绝置评。\n　　数月来，Abivax多次被传为是收购对象，其股价也因此飙升。\n　　在La Lettre的报道发布后，该公司股价周四一度上涨15%，但在午盘交易中涨幅约为4%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-12/doc-inhqtyyi4639257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B3T34201.USD","LU0289739699.SGD","LU0320765992.SGD","LU2462157665.USD","BK4568","LU0058720904.USD","AZN","LU0889565916.HKD","BK4007","LU1829250122.USD","LU2456880835.USD","LU2236285917.USD","LU0109394709.USD","LU2417539215.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"2618791903","title":"港股异动 | 康诺亚-B(02162)再涨超3% CMG901获阿斯利康4500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2618791903","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618791903?lang=zh_cn&edition=full","pubTime":"2026-03-12 09:51","pubTimestamp":1773280266,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B再涨超3%，截至发稿，涨2.21%，报55.5港元，成交额750.96万港元。根据许可协议条款及条件的规限下，上述临床试验完成首例受试者给药已触发相关里程碑付款，总金额为4500万美元。阿斯利康已支付该里程碑款项。公开资料显示，康诺亚和乐普生物合资设立的KYM Biosciences Inc.于2023年2年与阿斯利康订立全球独家许可协议，授权阿斯利康在全球范围开发及商业化CMG901。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4568","LU2456880835.USD","LU0320765992.SGD","LU1829250122.USD","BK1161","LU0109394709.USD","IE00B3T34201.USD","AZN","VXUS","BK1587","LU0289739699.SGD","BK4588","BK4585","LU2462157665.USD","BK1574","LU0889565916.HKD","LU0058720904.USD","LU2417539215.USD","02162","BK4007","LU2236285917.USD"],"gpt_icon":0},{"id":"2618924896","title":"英国央行降息预期减弱拖累富时100指数跌0.8% 阿斯利康与汇丰领跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2618924896","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618924896?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:55","pubTimestamp":1773219310,"startTime":"0","endTime":"0","summary":"（原标题：英国央行降息预期减弱拖累富时100指数跌0.8% 阿斯利康与汇丰领跌）金吾财讯|伦敦富时100指数周三延续跌势，下挫0.8%至10320点，因投资者调降对英国央行年内进一步降息的预期。权重股阿斯利康、汇丰控股与罗尔斯·罗伊斯引领大盘普跌，仅零售板块因Inditex亮眼财报获得支撑。尽管原油价格已从每桶100美元上方高位回落，但早前涨势已重塑市场预期——货币市场现预计2026年前降息概率微乎其微。企业财报方面，保险及投资管理集团Legal & General年度盈利虽增并宣布12亿英镑股票回购计划，但因偿付能力比率未达预期，股价重挫近6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117061397ad6c1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117061397ad6c1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU0109394709.USD","AZN","LU0058720904.USD","LU0320765992.SGD","LU1267930227.SGD","LU2456880835.USD","BK4007","HSBC","BK4207","LU1829250122.USD","LU0889565916.HKD","IE00B3T34201.USD","LU0052756011.USD","LU0128525689.USD","BK4521","LU2236285917.USD","LU2417539215.USD","LU2462157665.USD","BK4588","HSBH","BK4585","LU0310800965.SGD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2618157119","title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618157119?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","NVO","BK4599","NVOX","LU0154236417.USD","LU1093756325.SGD","BK4007","IE00BZ1G4Q59.USD","BK4585","BK4121","LU1093756168.USD","BK4532","LU0757428866.USD","NVOH","LU1815336091.USD","AZN","BK4530","LU0029874061.USD","INCY","REGN","IE00BFMHRM44.USD","BK4588","LU0390134368.USD","LU0128526141.USD"],"gpt_icon":0},{"id":"2618996353","title":"港股异动 | 加科思-B(01167)绩后涨超6% 2025年研发管线多点突破 与阿斯利康共同开发JAB-23E73","url":"https://stock-news.laohu8.com/highlight/detail?id=2618996353","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618996353?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:35","pubTimestamp":1773192931,"startTime":"0","endTime":"0","summary":"截至2025年12月31日，公司拥有380项在全球提交的有效专利或专利申请，其中146项专利已在全球主要市场获颁发或允许。年内，公司与AstraZeneca AB已订立许可与合作协议，共同开发及商业化泛KRAS抑制剂JAB-23E73。根据该许可及合作协议并受其条款及条件所限，北京加科思有权向阿斯利康收取1亿美元的预付款项，并有资格在达成特定开发、监管及商业里程碑时收取额外里程碑付款，总潜在代价最高可达19.15亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765992.SGD","LU2462157665.USD","BK4588","BK1574","01167","LU2236285917.USD","VXUS","LU0889565916.HKD","LU2417539215.USD","IE00B3T34201.USD","BK4568","LU0109394709.USD","AZN","LU0289739699.SGD","BK4007","BK4585","LU0058720904.USD","LU1829250122.USD","BK1161","LU2456880835.USD"],"gpt_icon":0},{"id":"2618939295","title":"康诺亚CMG901获阿斯利康4500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939295","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618939295?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:18","pubTimestamp":1773137907,"startTime":"0","endTime":"0","summary":"北京商报讯3月10日，康诺亚发布公告，更新了与AstraZeneca（阿斯利康）就核心产品CMG901（AZD0901）合作的最新情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667582417.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667582417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LU0320765992.SGD","02162","BK1583","LU0889565916.HKD","AZN","BK1574","LU2417539215.USD","BK1587","IE00B3T34201.USD","LU0109394709.USD","LU2462157665.USD","BK4007","LU2236285917.USD","BK4585","LU1829250122.USD","BK1161","LU0289739699.SGD","LU2456880835.USD","BK4568","LU0058720904.USD"],"gpt_icon":0},{"id":"2617635561","title":"顶尖药企竞相推出减重口服药","url":"https://stock-news.laohu8.com/highlight/detail?id=2617635561","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617635561?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:16","pubTimestamp":1772806560,"startTime":"0","endTime":"0","summary":"全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。　　这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。　　诺和诺德成为首家推出口服 GLP1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。　　中国歌礼制药的在研口服 GLP1 药物ASC30，在美国二期临床试验中最高减重7.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-06/doc-inhqanka2342553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000165453.HKD","SG9999002232.USD","SG9999001176.USD","BK4588","IE00BLSP4239.USD","LU0225284248.USD","SG9999013999.USD","BK1583","AZN","BK4581","LU1894683348.USD","LU2097828714.EUR","SG9999003800.SGD","LU0225771236.USD","LU1066053197.SGD","LU2097828557.USD","000963","LU2097828631.EUR","LU1057294990.SGD","LU1883839398.USD","LU0170899867.USD","LU2328871848.SGD","MRK","BK4533","LU0306806265.USD","LU2488822045.USD","SG9999001176.SGD","VKTX","SG9999011175.SGD","LU0321505439.SGD","LU0058720904.USD","PFE","LU0122379950.USD","LU1023059063.AUD","IE00BBT3K403.USD","BK4007","LLY","LU1066051498.USD","IE0002270589.USD","LU2097828474.EUR","IE000M9KFDE8.USD","LU2097828805.USD","BK4534","LU0234572021.USD","LU2242644610.SGD","RHHBY","LU0502904849.HKD","BK4550","SGXZ57979304.SGD","LU1969619763.USD","BK4585","LU0321505868.SGD","LU0456855351.SGD","IE00BLSP4452.SGD","01801","LU0306807586.USD","SG9999002224.SGD","BK4592","BK1161","LU0455707207.USD","LU0289739699.SGD","LU1894683264.USD","BK4568","LU0985481810.HKD","LU0868494617.USD","IE00B19Z3B42.SGD","BK1589","BK4599","IE00B19Z3581.USD","NVO"],"gpt_icon":1},{"id":"2617577596","title":"阿斯利康跌1.13% 股价跌破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2617577596","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617577596?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:31","pubTimestamp":1772721101,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日22时31分，阿斯利康股票出现波动，股价快速下挫1.13%。截至发稿，该股报199.26美元/股，成交量3.4768万股，换手率0.00%，振幅0.25%。最近的财报数据显示，该股实现营业收入587.39亿美元，净利润102.25亿美元，每股收益6.60美元，毛利438.47亿美元，市盈率30.47倍。机构评级方面，在所有31家参与评级的机构中，81%的券商给予买入建议，10%的券商给予持有建议，9%的券商给予卖出建议。阿斯利康股票所在的制药行业中，整体跌幅为1.21%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305223141a6a71f62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305223141a6a71f62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B3T34201.USD","LU0109394709.USD","LU2236285917.USD","BK4568","LU2462157665.USD","LU2417539215.USD","LU1829250122.USD","LU2456880835.USD","BK4585","BK4588","LU0058720904.USD","LU0320765992.SGD","AZN","LU0889565916.HKD","LU0289739699.SGD","BK4007"],"gpt_icon":0},{"id":"2617577516","title":"阿斯利康重磅炸弹在国内启动新 III 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2617577516","media":"求实药社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617577516?lang=zh_cn&edition=full","pubTime":"2026-03-05 12:03","pubTimestamp":1772683402,"startTime":"0","endTime":"0","summary":"来源：丁香园Insight数据库3 月 4 日，药物临床试验登记与信息公示平台官网显示，阿斯利康登记了一项特泽利尤单抗用于鼻内镜下鼻息肉评分 ≥4 分慢性鼻窦炎伴鼻息肉成人患者附加维持治疗的 IIIb 期临床研究。用药方案为每 4 周皮下注射一次，合计 24 周。通过精准阻断 TSLP，特泽利尤单抗可从源头抑制相关炎症通路激活，从而缓解疾病症状。目前，特泽利尤单抗已经在美国、日本、欧盟获批 2 项适应症，分别是哮喘、慢性鼻窦炎伴鼻息肉病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030514022597a82446&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030514022597a82446&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","IE00B3T34201.USD","LU2456880835.USD","LU0889565916.HKD","LU0289739699.SGD","BK4585","BK4588","LU0109394709.USD","LU1829250122.USD","III","LU2417539215.USD","BK4568","LU2462157665.USD","BK4134","LU0058720904.USD","AZN","BK4007","LU2236285917.USD"],"gpt_icon":0},{"id":"2614737497","title":"传AI芯片制造商Cerebras已秘密提交IPO申请 估值或达220亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614737497","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614737497?lang=zh_cn&edition=full","pubTime":"2026-02-25 10:34","pubTimestamp":1771986843,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据报道，与英伟达 和AMD竞争的人工智能芯片制造商Cerebras已秘密提交首次公开募股申请。此前的报道显示，Cerebras目标是在2026年第二季度进行首次公开募股。上月，Cerebras与OpenAI签署了一项价值数十亿美元的多年协议，为其提供750兆瓦的计算能力。据报道，Cerebras还在洽谈筹集10亿美元资金，这将使公司估值达到220亿美元。Cerebras最初于2024年9月申请公开上市，但因联邦政府对其与阿布扎比AI公司G42关系的审查而陷入停滞。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BN29S564.USD","SG9999014906.USD","LU1267930490.SGD","LU0320765059.SGD","IE00BWXC8680.SGD","LU2471134523.USD","LU2211815571.USD","LU1633808545.USD","LU1778281490.HKD","IE00BQXX3C00.GBP","BK4608","LU2326559502.SGD","SG9999014898.SGD","IE00B1XK9C88.USD","IE00B19Z9505.USD","SG9999014559.SGD","IE00B19Z8X17.USD","LU2065171311.SGD","SG9999015986.USD","LU0198837287.USD","AMDW","LU0097036916.USD","LU0158827948.USD","LU0708994859.HKD","LU2602419157.SGD","IE00B1BXHZ80.USD","NVII","AZN","LU1839511570.USD","IE0034235303.USD","LU1815336760.USD","LU0234570918.USD","LU0708995401.HKD","IE00B775SV38.USD","SG9999002224.SGD","LU0979878070.USD","LU0820561818.USD","LU1951198990.SGD","NVDU","BK4533","IE0034235188.USD","IE00BHPRN162.USD","LU1303367103.USD","LU2077746001.SGD","LU1629891620.HKD","NVDB","NVDG","LU0053666078.USD","LU1989772923.USD","LU1280957306.USD","LU0266013472.USD","SG9999014880.SGD","NVDS.UK","LU0689626769.HKD","LU2168564065.EUR","LU1244550577.SGD","LU1153585028.USD","LU0390134368.USD","LU2458330243.SGD","BK4585","IE00BFSS7M15.SGD","IE00BJJMRX11.SGD","LU2430703251.USD","IE00BYXW3230.USD","LU2750360641.GBP","LU0672654240.SGD","BK4566","LU2452424414.USD","LU1267930730.SGD","LU1718418525.SGD","LU2213496289.HKD","LU2433249047.HKD","LU0096364046.USD","LU1935042991.SGD","LU2473716301.USD","LU1989764664.SGD","AMDU","BK4141","LU0082616367.USD","LU0494093205.USD","BK4527","LU2023251221.USD","LU1935042488.USD","SG9999014542.SGD","IE00BZ199S13.USD","LU0444973449.USD","BK4551","LU0061474960.USD","LU2242650005.HKD","LU1366333091.USD","LU1821325948.USD","BK4550","LU0157215616.USD","LU1935042215.USD","BK4567","LU0965509010.AUD","IE00BKPKM429.USD","LU2125154935.USD","LU1712237335.SGD","LU2054465674.USD","LU0557290698.USD","SG9999015341.SGD","LU0238689110.USD","LU1116320737.USD","LU1496350502.SGD","LU0354030511.USD","LU0251132253.USD","LU0225283273.USD","LU2065169927.USD","LU2242649171.HKD","LU1868836591.USD","LU1066051498.USD","IE000YTNTUN2.SGD","LU2746668974.SGD","LU0256863902.USD","LU2458330169.SGD","LU1064131342.USD","HK0000320223.HKD","LU0353189680.USD","LU2491049909.HKD","LU1868837300.USD","BK4543","LU1934455863.HKD","LU2065171402.SGD","LU2271345857.HKD","LU0965508806.USD","SG9999001424.SGD","LU2491050071.SGD","LU2065170008.USD","LU0417517546.SGD","LU2361044949.HKD","LU2265009873.SGD","LU1720051108.HKD","LU1989764748.USD","LU2360032135.SGD","LU1548497426.USD","LU1814569148.SGD","LU1242518931.SGD","IE00BJLML261.HKD","LU0203201768.USD","LU1861559042.SGD","LU1868836914.USD","LU0820562030.AUD","LU0786609619.USD","LU0820561909.HKD","LU0823434740.USD","BK4587","LU0942090050.USD","LU0274383776.USD","LU1934455194.USD","IE00BK4W5L77.USD","LU0683600562.USD","LU2552382215.SGD","SG9999000418.SGD","LU0345768153.USD","DIPS","LU1691799644.USD","LU1316542783.SGD","LU2543165471.USD","LU2247934214.USD","LU2168564222.USD","LU0203202063.USD","LU2237957811.SGD","LU2487616109.SGD","LU2592432038.USD","LU0345768740.USD","LU1880398554.USD","NVD3.UK","IE0009G5SDU7.USD","BK4592","LU2098885051.SGD","LU2931357623.SGD","HK0000306701.USD","LU2237438978.USD","LU1989772840.SGD","SG9999015945.SGD","LU0187121727.USD","LU2756315664.SGD","LU0985320562.USD","LU0079474960.USD","IE0004445015.USD","LU2430703095.HKD","NVDX","LU0154236417.USD","LU0029864427.USD","LU2063271972.USD","LU0276348264.USD","IE00BD6J9T35.USD","LU1917777945.USD","BK4549","LU1037948897.HKD","LU0210533765.USD","LU0310800379.SGD","LU2357125470.USD","LU1037948541.HKD","LU0057025933.USD","LU2403377893.USD","LU0943347566.SGD","LU2505996681.GBP","LU1914381329.SGD","LU2322448957.HKD","LU2083900584.USD","LU0215105999.USD","LU0308772762.SGD","LU2462157665.USD","BK4534","AMYY","LU2111349929.HKD","LU0210536198.USD","LU2087625088.SGD","LU2097344357.USD","LU1674673428.USD","LU0957791311.USD","SG9999014914.USD","LU1923623000.USD","IE000W1ABFV2.USD","HK0000914686.HKD","SGXZ31699556.SGD","LU0787776722.HKD","LU0964807845.USD","LU2290526834.HKD","LU1435385759.SGD","LU0211327993.USD","LU1934455277.USD","LU0868494708.USD","BK4512","HK0000914660.USD","LU2028103732.USD","LU1923622614.USD","LU2168563687.JPY","LU0823414551.USD","BK4529","LU2092937148.SGD","LU2125909247.SGD","LU2272731782.SGD","LU2089284900.SGD","IE00BFSS8Q28.SGD","LU1720051017.SGD","LU1935043023.USD","AMDD","LU2746668461.USD","NVDY","LU0124676726.USD","LU1642822529.SGD","LU1699723380.USD","NVDW","LU2106854487.HKD","IE00BQXX3F31.USD","LU0289960550.SGD","IE00BMPRXN33.USD","LU2430703178.SGD","LU0106261372.USD","LU1084165304.USD","SG9999014567.USD","IE0003U64NQ7.SGD","LU2505996509.AUD","IE0004091025.USD","LU2360106780.USD","LU2236285917.USD","LU2471134796.USD","LU2552382132.HKD","AMDY","LU0265550359.USD","GB00BDT5M118.USD","IE00B19Z8W00.USD","LU1988902786.USD","IE00BK4W5M84.HKD","LU0823421416.USD","LU0861579265.USD","2NVD.UK","LU1127390331.HKD","LU2322448791.USD","BK4598","LU2381873111.SGD","HK0000320264.USD","BK4573","LU2357305700.SGD","NVDD","LU1551013425.SGD","LU0072462426.USD","LU1791710582.SGD","LU0348723411.USD","LU1804176565.USD","LU0965509283.SGD","LU2552382058.USD","LU0069063385.USD","LU2463028550.USD","LU0265550946.USD","SGXZ99366536.SGD","LU2087621335.USD","SGXZ51526630.SGD","LU0823434583.USD","LU0719512351.SGD","LU1623119135.USD","NVD","LU1861220033.SGD","LU0889565833.HKD","BK4612","IE00B4JS1V06.HKD","LU2272731600.USD","LU0689472784.USD","IE00B4YYXB79.USD","LU2286300806.USD","LU0006306889.USD","LU2097344431.USD","LU2420271590.USD","IE00BJTD4V19.USD","LU2089283258.USD","IE00B3SWFQ91.USD","LU2125909759.SGD","NVDQ","LU2461242641.AUD","LU2168564149.EUR","HK0000306685.HKD","LU1861127337.USD","BK4614","BK4579","LU0128525929.USD","LU1571399168.USD","LU2092627202.USD","LU1868837136.USD","LU0965509101.SGD","LU0353189763.USD","LU2250418816.HKD","LU0234572021.USD","LU2491050154.USD","IE00BZ1G4Q59.USD","SGXZ81514606.USD","LU1261432733.SGD","LU2125154778.USD","SG9999018865.SGD","LU2750360997.AUD","LU0724617625.USD","LU1242518857.USD","LU0868494617.USD","IE00BDCRKT87.USD","LU0476273544.USD","LU0957808578.USD","AMUU","LU0127658192.USD","LU0345770993.USD","IE00BJTD4N35.SGD","LU0823421333.USD","LU2168564495.EUR","LU1861215975.USD","IE000ITXATA3.USD","BK4503","LU0345769631.USD","LU1119994496.HKD","IE00BKVL7J92.USD","LU0080751232.USD","LU1974910355.USD","IE00B3M56506.USD","LU1861558580.USD","BK4605","IE0009356076.USD","SG9999015358.SGD","LU1983260115.SGD","LU1674673691.USD","LU0175139822.USD","LU1551013342.USD","LU1992135472.HKD","LU0354030438.USD","LU0211328371.USD","IE0034235295.USD","LU0345770308.USD","IE00BMPRXQ63.HKD","SG9999014575.USD","IE00BQXX3D17.EUR","NVIW.SI","LU1244550221.USD","LU1429558221.USD","LU0109392836.USD","BK4581","LU0310799852.SGD","IE00B775H168.HKD","IE0004445239.USD","LU1721428933.USD","LU0472753341.HKD","LU2023250330.USD","LU0289739343.SGD","IE0005OL40V9.USD","LU0210528500.USD","LU0061474705.USD","ANV","BK4588","LU2023250504.SGD","LU0096362180.USD","SG9999015952.SGD","LU0466842654.USD","LU2361044865.SGD","IE00B5949003.HKD","LU1880398471.USD","NVDS","LU2244417387.USD","LU2361045086.USD","IE00B7KXQ091.USD","LU0158827781.USD","LU0642271901.SGD","LU2417539215.USD","LU2471134952.CNY","LU0077335932.USD","LU0070217475.USD","LU2456880835.USD","LU0347712357.USD","LU0107464264.USD","LU0882574139.USD","SG9999018857.SGD","LU1935043536.SGD","LU1791710400.SGD","IE00BMPRXR70.SGD","LU0444971666.USD","LU2355687059.USD","IE00BJJMRY28.SGD","LU0788109477.HKD","LU1951200564.SGD","LU1852331112.SGD","BK4532","LU0640476718.USD","IE00B3S45H60.SGD","LU0011850046.USD","LU1815333072.USD","LU2249611893.SGD","IE00BDRTCR15.USD","LU2272731865.HKD","LU1145028129.USD","LU0289961442.SGD","BK4548","LU1066051811.HKD","LU0094547139.USD","LU1069344957.HKD","LU2125909593.SGD","SG9999015978.USD","LU0323591593.USD","LU0511384066.AUD","LU2413666426.HKD","LU0528227936.USD","LU0256863811.USD","LU1267930573.SGD","SG9999017495.SGD","LU1868836757.USD","SGXZ23171101.USD","IE0004086264.USD","BK4554","LU0170899867.USD","LU2237957902.USD","LU2360107168.USD","LU0823414478.USD","LU1066053197.SGD","LU0267386448.USD","LU0109391861.USD","LU1066051225.USD","LU2125909916.SGD","SG9999004303.SGD","LU1496350171.SGD","NVD2.UK","LU1232071149.USD","LU0081259029.USD","LU1035775433.USD","LU2264538146.SGD","LU2506951792.HKD","LU0342679015.USD","SG9999002232.USD","IE0001KFT4U8.USD","LU2089985449.USD","AMDG","DAMD","LU1366192091.USD","LU2756315318.SGD","LU2471134879.HKD","LU1923622291.USD","LU2108987350.USD","LU1992135399.USD","LU2294711713.HKD","LU2191332357.HKD","LU2860962120.EUR","IE000KEQY171.SGD","LU0056508442.USD","LU1116320901.HKD","LU0345769128.USD","LU1244550494.USD","SNVD.UK","LU1323610961.USD","LU2413666699.HKD","BK4575","LU0316494557.USD","LU2896262040.SGD","LU0061475181.USD","LU1803068979.SGD","3NVD.UK","LU0048584097.USD","IE00BKDWB100.SGD"],"gpt_icon":1},{"id":"2611486068","title":"超级大洗牌！跨国药企中国市场最新排名","url":"https://stock-news.laohu8.com/highlight/detail?id=2611486068","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611486068?lang=zh_cn&edition=full","pubTime":"2026-02-16 23:02","pubTimestamp":1771254130,"startTime":"0","endTime":"0","summary":"1月份，跨国药企基本都披露了2025年业绩。礼来则以45%的增幅，营收达651.79亿美元成功反超默沙东，排名第三。而在中国市场，2025年1月，替尔泊肽降糖和减重两项适应症相继上市。2022年至2024年，阿斯利康与默沙东争夺跨国药企中国区营收的“NO.1”，“销售一哥”的宝座每年轮流坐庄。此外，诺华已宣布在中国建立核药生产基地，以支持“派威妥”等放射性药物在中国市场的长期供应。跨国药企把全球创新好药带到中国，才是最好的市场策略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","KWEB","AZN","MRK","CQQQ","BK4007","DRAG","LU1093756168.USD","NVOH","IE00BZ1G4Q59.USD","ASHS","BK4588","RHHBY","BK4599","LU1093756325.SGD","LU0963586101.USD","BK4614","NVS","BK4504","NVO","ASHR","CWEB","MCHI","IE00BKVL7J92.USD","NVOX","LLY","LU0154236417.USD","BK4532"],"gpt_icon":1},{"id":"2611713190","title":"倍择瑞®治疗未控制哮喘的KALOS与LOGOS III期试验取得具有临床意义的阳性结果 相关成果发表于《柳叶刀-呼吸病学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=2611713190","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611713190?lang=zh_cn&edition=full","pubTime":"2026-02-13 15:43","pubTimestamp":1770968580,"startTime":"0","endTime":"0","summary":"完整结果可查阅《柳叶刀-呼吸病学杂志》。KALOS与LOGOS试验表明，布地格福固定三联吸入疗法能够同时发挥ICS、LAMA和LABA的疗效，改善肺功能。KALOS与LOGOS研究结果有力地证实，布地格福固定三联吸入疗法有望为该类型哮喘患者带来健康获益。\" 在KALOS与LOGOS试验中，布地格福吸入气雾剂未出现新的安全性或耐受性问题。KALOS与LOGOS研究共纳入约4300名随机分组患者。KALOS和LOGOS试验的主要终点和治疗比较方案因监管申报途径的不同而有所差异。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4887756_ZH87756_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0289739699.SGD","LU0320765992.SGD","LU2462157665.USD","BK4134","BK4568","LU0058720904.USD","AZN","III","LU0889565916.HKD","BK4007","LU1829250122.USD","LU2456880835.USD","LU2236285917.USD","LU0109394709.USD","LU2417539215.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"1196396752","title":"异动解读 | 业绩强劲叠加口服减肥药进展，阿斯利康盘中大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196396752","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196396752?lang=zh_cn&edition=full","pubTime":"2026-02-12 01:21","pubTimestamp":1770830507,"startTime":"0","endTime":"0","summary":"阿斯利康(AZN)今日盘中大涨5.02%，表现强势。消息面上，公司最新发布的2025年业绩表现亮眼，全年总营收达587.39亿美元，同比增长8%，其中中国区营收66.54亿美元创历史新高。同时，公司宣布了未来几年在中国的巨额投资计划，彰显了对该市场长期增长的信心。此外，公司在热门减肥药领域的管线取得关键进展，其口服GLP-1受体激动剂elecoglipron在2b期临床试验中达到主要终点，即将进入三期临床开发阶段，这为公司在竞争激烈的减肥药市场增添了重要筹码。公司对2026年业绩给出了中高个位数增长的乐观预期，多重利好共同推动了股价的上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AZN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0068},{"period":"1month","weight":-0.0869},{"period":"3month","weight":0.0121},{"period":"6month","weight":0.2686},{"period":"1year","weight":0.2809},{"period":"ytd","weight":0.0178}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0375},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.1414},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.545455,"avgChangeRate":0.024046},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018334},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}